News - Metabolics, GlaxoSmithKline

Filter

Current filters:

MetabolicsGlaxoSmithKline

Popular Filters

1 to 25 of 531 results

GSK confirms further misconduct allegations, now in Jordan and Lebanon

17-04-2014

There has been recent publicity on cases of alleged misconduct by UK Pharma giant GlaxoSmithKline employees…

GlaxoSmithKlineJordanMarkets & MarketingPharmaceuticalRegulationRest of the World

FDA finally OKs GlaxoSmithKline’s Tanzeum to treat type 2 diabetes

FDA finally OKs GlaxoSmithKline’s Tanzeum to treat type 2 diabetes

16-04-2014

UK pharma giant GlaxoSmithKline yesterday received the much anticipated approval from the US Food and…

albiglutideDiabetesGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationTanzeumUSA

Prosonix and Mylan in deal for Flixotide and Flovent generics

15-04-2014

Prosonix, a UK-based company which is developing a portfolio of inhaled “Respiratory Medicines by Design,”…

FloventGenericsGlaxoSmithKlineGlobalLicensingMylan LaboratoriesProsonixRespiratory and Pulmonary

GSK faces bribery allegations in Poland

GSK faces bribery allegations in Poland

14-04-2014

UK pharma major GlaxoSmithKline is facing allegations of bribing doctors in Poland, according to the…

BBCGlaxoSmithKlineGSK regional managerLegalMajorMedicinePharmaceuticalPolandPulmonologyRespiratory and PulmonarySeretideUK

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

09-04-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyGlaxoSmithKlineNorthern EuropeOncologyPharmaceuticalPricingRegulationTafinlarvemurafenib

Teva launches first generic Lovaza in USA

Teva launches first generic Lovaza in USA

08-04-2014

Israel-based Teva Pharmaceutical Industries says it has received US Food and Drug Administration approval…

Cardio-vascularGenericsGlaxoSmithKlineLovazaMarkets & MarketingRegulationTeva Pharmaceutical IndustriesUSA

GSK faces fresh allegations of “inproper conduct” in Iraq

GSK faces fresh allegations of “inproper conduct” in Iraq

08-04-2014

UK pharma major GlaxoSmithKline is facing allegations of bribery in Iraq, less than a year after the…

ChinaGlaxoSmithKlineGSKIraqMajorPharmaceuticalRegulationUK

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

04-04-2014

World leading independent biotech firm Amgen revealed in a Securities and Exchange Commission filing…

AmgenAnti-Arthritics/RheumaticsBiotechnologyGlaxoSmithKlineLicensingProliaXgeva

UCB enters strategic alliance with Weill-Cornell in three discovery projects

03-04-2014

Belgian drugmaker UCB has launched a major, three-year strategic research alliance with Weill-Cornell…

MetabolicsPharmaceuticalRare diseasesResearchUCB

GlaxoSmithKline targets strategic investments in Africa

02-04-2014

Speaking at the 5th EU-Africa Business Forum in Brussels this week, Sir Andrew Witty, chief executive…

FinancialGlaxoSmithKlineHealthcarePharmaceuticalRest of the WorldSouth Africa

GSK drops Phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic in NSCLC

GSK drops Phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic in NSCLC

02-04-2014

UK pharma major GlaxoSmithKline will stop its MAGRIT trial, a Phase III trial of its MAGE-A3 cancer immunotherapeuticin…

GlaxoSmithKlineMAGE-A3OncologyPharmaceuticalResearchUK

GSK withdraws European marketing authorization for ovarian cancer drug Votrient

GSK withdraws European marketing authorization for ovarian cancer drug Votrient

31-03-2014

UK pharma major GlaxoSmithKline has withdrawn its application to the European Medicines Agency for a…

GlaxoSmithKlineOncologyPharmaceuticalRegulationUKVotrientWomen's Health

ACC 2014: GSK’s darapladib disappoints in Ph III trial

ACC 2014: GSK’s darapladib disappoints in Ph III trial

31-03-2014

UK pharma major GlaxoSmithKline (LSE: GSK) presented disappointing data from its pivotal Phase III STABILITY…

Cardio-vasculardarapladibGlaxoSmithKlinePharmaceuticalResearchUKUSA

GSK acquires remaining 30% of its Indonesian Consumer Healthcare business

GSK acquires remaining 30% of its Indonesian Consumer Healthcare business

28-03-2014

US pharma giant GlaxoSmithKline has acquired full ownership of its Indonesian Consumer Healthcare business…

Asia-PacificGlaxoSmithKlineIndonesiaMergers & AcquisitionsPharmaceuticalProduction

Factors driving oncologists’ prescribing decisions for HER2-positive breast cancer patients

Factors driving oncologists’ prescribing decisions for HER2-positive breast cancer patients

28-03-2014

Efficacy, more than any other factors, drives oncologists’ prescribing of targeted therapies for breast…

AfinitorbuparlisibGlaxoSmithKlineHerceptinMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRocheTykerb

SOBI’s Kiobrina pivotal Ph III study fails to meet primary endpoint

SOBI’s Kiobrina pivotal Ph III study fails to meet primary endpoint

27-03-2014

Stockholm-based Swedish Orphan Biovitrum has released disappointing top-line results from a Phase III…

BiotechnologyKiobrinaMetabolicsResearchSwedish Orphan Biovitrum

Mylan prevails in breach of contract case against GlaxoSmithKline

Mylan prevails in breach of contract case against GlaxoSmithKline

27-03-2014

US generics major Mylan reveals that, after a trial in the US District Court for the District of New…

GenericsGlaxoSmithKlineLegalMylan LaboratoriesNeurologicalparoxetinePaxil-CR

GSK announces delay in Mekinist/Tafinlar MAA; EU approval of Eperzan

GSK announces delay in Mekinist/Tafinlar MAA; EU approval of Eperzan

27-03-2014

UK pharma giant GlaxoSmithKline released a couple of news items yesterday, one slightly negative regarding…

DiabetesEperzanEuropeGlaxoSmithKlineMekinistOncologyPharmaceuticalRegulationTafinlar

Novel collaboration to use genomics and big data to drive drug discovery

27-03-2014

A pioneering public-private research initiative between UK pharma giant GlaxoSmithKline, the European…

BiotechnologyEuropeGlaxoSmithKlineResearch

GlaxoSmithKline’s MAGE-A3 fails in Ph III NSCLC trial

GlaxoSmithKline’s MAGE-A3 fails in Ph III NSCLC trial

20-03-2014

There was another setback for UK pharma giant GlaxoSmithKline with its MAGE-A3 antigen specific cancer…

AgenusGlaxoSmithKlineMAGE-A3OncologyPharmaceuticalResearch

1 to 25 of 531 results

Back to top